OptimizeRx Corp. (NASDAQ:OPRX) Receives $17.57 Consensus Target Price from Analysts
by Michael Walen · The Markets DailyOptimizeRx Corp. (NASDAQ:OPRX – Get Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $17.5714.
Several equities research analysts have issued reports on OPRX shares. Roth Mkm decreased their price objective on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Stephens cut their target price on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th. B. Riley Financial restated a “buy” rating and set a $11.00 target price (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Lake Street Capital decreased their price target on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Finally, Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, March 13th.
Get Our Latest Research Report on OPRX
Institutional Trading of OptimizeRx
Several large investors have recently bought and sold shares of OPRX. Quantbot Technologies LP acquired a new position in shares of OptimizeRx during the second quarter worth $44,000. BNP Paribas Financial Markets grew its holdings in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in OptimizeRx during the 4th quarter valued at $62,000. USA Financial Formulas purchased a new stake in OptimizeRx during the 3rd quarter worth $131,000. Finally, ExodusPoint Capital Management LP purchased a new stake in OptimizeRx during the 4th quarter worth $150,000. Institutional investors and hedge funds own 76.47% of the company’s stock.
OptimizeRx Stock Performance
NASDAQ OPRX opened at $6.25 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.04 and a quick ratio of 3.04. OptimizeRx has a 1-year low of $5.54 and a 1-year high of $22.25. The firm has a market capitalization of $117.16 million, a P/E ratio of 24.02 and a beta of 1.20. The business’s 50-day simple moving average is $8.39 and its 200-day simple moving average is $13.37.
OptimizeRx (NASDAQ:OPRX – Get Free Report) last posted its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. Equities analysts predict that OptimizeRx will post -0.33 EPS for the current year.
OptimizeRx declared that its board has approved a stock repurchase program on Thursday, March 5th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.
OptimizeRx Company Profile
OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.
The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.